Otelixizumab

N/A

Report date: 2023/09/27 20:12:00

Base Information

Drug NameOtelixizumab
Drug Alias Nameotelixizumabum奥昔珠单抗奥利昔珠单抗GSK-2136525ChAglyCD3 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionImmunosuppressantsT cell surface glycoprotein CD3 inhibitors
TargetsT cell surface glycoprotein CD3
Therapy Area/IndicationsDiabetes Mellitus, Type 1Graves OphthalmopathyArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[12] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBtg Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline PlcUniversiteit Antwerpen
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 1Graves OphthalmopathyArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG